Amgen reported solid revenue growth and maintained its share buyback program, which are positive signs. However, the uncertainty surrounding ESA label changes and the upcoming CMS decision introduce short-term risks that may weigh on the stock. Overall, the mixed signals suggest potential downward pressure in the near term.

[-1]